These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 21175581)

  • 1. Low dose of the liver X receptor agonist, AZ876, reduces atherosclerosis in APOE*3Leiden mice without affecting liver or plasma triglyceride levels.
    van der Hoorn J; Lindén D; Lindahl U; Bekkers M; Voskuilen M; Nilsson R; Oscarsson J; Lindstedt E; Princen H
    Br J Pharmacol; 2011 Apr; 162(7):1553-63. PubMed ID: 21175581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The liver X receptor agonist AZ876 protects against pathological cardiac hypertrophy and fibrosis without lipogenic side effects.
    Cannon MV; Yu H; Candido WM; Dokter MM; Lindstedt EL; Silljé HH; van Gilst WH; de Boer RA
    Eur J Heart Fail; 2015 Mar; 17(3):273-82. PubMed ID: 25684370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel potent synthetic steroidal liver X receptor agonist lowers plasma cholesterol and triglycerides and reduces atherosclerosis in LDLR(-/-) mice.
    Peng D; Hiipakka RA; Xie JT; Dai Q; Kokontis JM; Reardon CA; Getz GS; Liao S
    Br J Pharmacol; 2011 Apr; 162(8):1792-804. PubMed ID: 21232031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanoparticles containing a liver X receptor agonist inhibit inflammation and atherosclerosis.
    Zhang XQ; Even-Or O; Xu X; van Rosmalen M; Lim L; Gadde S; Farokhzad OC; Fisher EA
    Adv Healthc Mater; 2015 Jan; 4(2):228-36. PubMed ID: 25156796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver X receptor agonist methyl-3β-hydroxy-5α,6α-epoxycholanate attenuates atherosclerosis in apolipoprotein E knockout mice without increasing plasma triglyceride.
    Yan W; Zhang T; Cheng J; Zhou X; Qu X; Hu H
    Pharmacology; 2010; 86(5-6):306-12. PubMed ID: 21071998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted Nanotherapeutics Encapsulating Liver X Receptor Agonist GW3965 Enhance Antiatherogenic Effects without Adverse Effects on Hepatic Lipid Metabolism in Ldlr
    Yu M; Amengual J; Menon A; Kamaly N; Zhou F; Xu X; Saw PE; Lee SJ; Si K; Ortega CA; Choi WI; Lee IH; Bdour Y; Shi J; Mahmoudi M; Jon S; Fisher EA; Farokhzad OC
    Adv Healthc Mater; 2017 Oct; 6(20):. PubMed ID: 28730752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver X receptor activation promotes macrophage-to-feces reverse cholesterol transport in a dyslipidemic hamster model.
    Briand F; Tréguier M; André A; Grillot D; Issandou M; Ouguerram K; Sulpice T
    J Lipid Res; 2010 Apr; 51(4):763-70. PubMed ID: 19965597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Raising HDL cholesterol without inducing hepatic steatosis and hypertriglyceridemia by a selective LXR modulator.
    Miao B; Zondlo S; Gibbs S; Cromley D; Hosagrahara VP; Kirchgessner TG; Billheimer J; Mukherjee R
    J Lipid Res; 2004 Aug; 45(8):1410-7. PubMed ID: 15145986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LXR agonist suppresses atherosclerotic lesion growth and promotes lesion regression in apoE*3Leiden mice: time course and mechanisms.
    Verschuren L; de Vries-van der Weij J; Zadelaar S; Kleemann R; Kooistra T
    J Lipid Res; 2009 Feb; 50(2):301-11. PubMed ID: 18757914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue-specific liver X receptor activation promotes macrophage reverse cholesterol transport in vivo.
    Yasuda T; Grillot D; Billheimer JT; Briand F; Delerive P; Huet S; Rader DJ
    Arterioscler Thromb Vasc Biol; 2010 Apr; 30(4):781-6. PubMed ID: 20110577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. QiShenYiQi pill inhibits atherosclerosis by promoting TTC39B-LXR mediated reverse cholesterol transport in liver.
    Wang TT; Yang CY; Peng L; Li L; Chen NT; Feng X; Xie J; Wu TC; Xu T; Chen YZ
    Phytomedicine; 2024 Jan; 123():155192. PubMed ID: 37951148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthetic LXR agonist attenuates plaque formation in apoE-/- mice without inducing liver steatosis and hypertriglyceridemia.
    Kratzer A; Buchebner M; Pfeifer T; Becker TM; Uray G; Miyazaki M; Miyazaki-Anzai S; Ebner B; Chandak PG; Kadam RS; Calayir E; Rathke N; Ahammer H; Radovic B; Trauner M; Hoefler G; Kompella UB; Fauler G; Levi M; Levak-Frank S; Kostner GM; Kratky D
    J Lipid Res; 2009 Feb; 50(2):312-26. PubMed ID: 18812595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Skeletal muscle as a target of LXR agonist after long-term treatment: focus on lipid homeostasis.
    Archer A; Laurencikiene J; Ahmed O; Steffensen KR; Parini P; Gustafsson JÅ; Korach-André M
    Am J Physiol Endocrinol Metab; 2014 Mar; 306(5):E494-502. PubMed ID: 24368671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LXR Agonist T0901317's Hepatic Impact Overrules Its Atheroprotective Action in Macrophages, Driving Early Atherogenesis in Chow-Diet-Fed Male Apolipoprotein E Knockout Mice.
    Hoekstra M; de Jong LM; van der Geest R; de Leeuw LR; Krisnamurthi R; Geerling JJ; Van Eck M
    Biomolecules; 2024 Apr; 14(4):. PubMed ID: 38672446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of notch enhances the anti-atherosclerotic effects of LXR agonists while reducing fatty liver development in ApoE-deficient mice.
    Hao Y; Wang X; Zhang F; Wang M; Wang Y; Wang H; Du Y; Wang T; Fu F; Gao Z; Zhang L
    Toxicol Appl Pharmacol; 2020 Nov; 406():115211. PubMed ID: 32853627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The dual PPARalpha/gamma agonist tesaglitazar blocks progression of pre-existing atherosclerosis in APOE*3Leiden.CETP transgenic mice.
    van der Hoorn JW; Jukema JW; Havekes LM; Lundholm E; Camejo G; Rensen PC; Princen HM
    Br J Pharmacol; 2009 Apr; 156(7):1067-75. PubMed ID: 19220285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver X Receptor Agonist AZ876 Induces Beneficial Endogenous Cardiac Lipid Reprogramming and Protects Against Isoproterenol-Induced Cardiac Damage.
    Ritter D; Goeritzer M; Thiele A; Blumrich A; Beyhoff N; Luettges K; Smeir E; Kasch J; Grune J; Müller OJ; Klopfleisch R; Jaeger C; Foryst-Ludwig A; Kintscher U
    J Am Heart Assoc; 2021 Jul; 10(14):e019473. PubMed ID: 34227403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein/presenilin 1 mice.
    Donkin JJ; Stukas S; Hirsch-Reinshagen V; Namjoshi D; Wilkinson A; May S; Chan J; Fan J; Collins J; Wellington CL
    J Biol Chem; 2010 Oct; 285(44):34144-54. PubMed ID: 20739291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The liver X receptor agonist GW3965 improves recovery from mild repetitive traumatic brain injury in mice partly through apolipoprotein E.
    Namjoshi DR; Martin G; Donkin J; Wilkinson A; Stukas S; Fan J; Carr M; Tabarestani S; Wuerth K; Hancock RE; Wellington CL
    PLoS One; 2013; 8(1):e53529. PubMed ID: 23349715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver X Receptor Regulates Triglyceride Absorption Through Intestinal Down-regulation of Scavenger Receptor Class B, Type 1.
    Briand O; Touche V; Colin S; Brufau G; Davalos A; Schonewille M; Bovenga F; Carrière V; de Boer JF; Dugardin C; Riveau B; Clavey V; Tailleux A; Moschetta A; Lasunción MA; Groen AK; Staels B; Lestavel S
    Gastroenterology; 2016 Mar; 150(3):650-8. PubMed ID: 26602218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.